WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
WuXi PharmaTech has enjoyed a close and cooperative relationship with Pfizer for many years, with collaborations ranging from synthetic chemistry, parallel medicinal chemistry (PMC), and ADME to bioanalytical services.
"This new agreement further strengthens our already productive
relationship with Pfizer, one of our largest customers for many years, and it
is the direct result of our research capability and firm commitment to quality
and customer satisfaction," commented Dr.
Under the new collaboration agreement WuXi PharmaTech in partnership with Pfizer will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer.
"A high quality and flexible Asia R&D partnership network is critical to
Pfizer's emerging market and
The evaluation of ADME properties is a key step in the drug discovery and development process. WuXi will evaluate ADME properties for Pfizer compounds with the goal of providing this key information to assist Pfizer scientists to improve the pharmacokinetic properties of their compounds.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
device R&D outsourcing company, with operations in
For more information, please contact: Sherry Shao WuXi PharmaTech (Cayman) Inc. Tel: +86-21-5046-4002 Email: email@example.com
SOURCE WuXi PharmaTech